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In this issue of Critical Care, Aliberti and colleagues [1] 
examine the question of whether acidemia predicts 
outcome in patients admitted with acute cardiogenic 
pulmonary edema (ACPE) and treated with continuous 
positive airway pressure (CPAP). Th   e authors performed 
a retrospective observational study in a large cohort of 
patients admitted to the emergency department with 
ACPE and treated with CPAP. Th  e authors compared 
treatment failure, deﬁ   ned as a switch to bi-level or 
invasive ventilation or in-hospital mortality, in two 
matched groups of patients with and without acidemia 
on admission. Th  e main conclusion was that neither 
admission acidemia nor type was an adverse prognostic 
marker.
Acute heart failure syndromes (AHFSs) are the most 
common reason for hospital admission in patients older 
than 65 years, over 50% of whom present with ACPE [2], 
and up to 10% of patients with ACPE will not survive 
their admission [3]. A number of prognostic factors have 
been identiﬁ  ed: age, systolic blood pressure (SBP), brain 
natriu  retic peptide or troponin rise, hyponatremia, renal 
dysfunction, previous ischemic heart disease, ejection 
fraction, and function at discharge. However, most of 
these variables have been used across the whole spectrum 
of AHFSs and relate to longer-term outcome [4,5]. 
Focusing on ACPE only, the 3CPO Trialists identiﬁ  ed 
patients at immediate risk of death and in need of inter-
vention on presentation; a simple score based on age, 
SBP, and the ability to obey commands predicted early 
mortality [6].
In acute exacerbations of chronic obstructive pulmo-
nary disease, acidosis is a strong predictor of adverse 
outcome [7]. Why does it not have similar prognostic 
implications in ACPE? Acidosis in hypercapnic respira-
tory failure is a direct reﬂ  ection of organ dys  function, in 
particular the failure of the lungs to ventilate the alveoli 
adequately. In contrast, in ACPE, acidosis is only an 
indirect conse  quence of cardiac dysfunction caused by a 
combination of factors, including edema-impaired gas 
exchange and tissue hypoperfusion. Th  e absence of 
acidosis is unusual in patients with ACPE [1]. It is 
therefore not surprising that acidosis is a poor 
discriminator of outcome. More direct indicators of 
cardiac function, such as cardiac power output (CPO), 
which is derived from the product of cardiac output and 
mean arterial blood pressure, have been shown to be 
powerful prognostic indicators in patients with AHFS, 
chronic heart failure (CHF), or cardiogenic shock [8-10].
Clinical risk scores, a product of statistical modeling, 
are a popular tool to identify prognostic markers. 
However, most do not pass the acid test of clinical utility, 
and this is evidence that a change in risk score correlates 
with changes in patient outcome. Furthermore, most risk 
scores do not provide any information on underlying 
pathophysiology.
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Several prognostic markers have been identifi  ed for 
patients admitted with acute cardiogenic pulmonary 
edema. Most of the markers are based on clinical 
risk scores. Unlike hypercapnic respiratory failure, 
acidosis is not an adverse predictor in these patients. 
Hemodynamic variables that assess pathophysiological 
mechanisms may be more helpful to guide appropriate 
management.
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© 2010 BioMed Central LtdDiﬀ  erentiating the pathophysiological processes under-
pinning the diﬀ  erent AHFSs to provide appropriate and 
rational treatment is an alternative approach to risk-
stratify patients with ACPE. Cotter and colleagues [11] 
suggested four major clinical AHFSs: (a) pulmonary 
edema, (b) cardiogenic shock, (c) hypertensive (HTN) 
crisis, and (d) exacerbated systolic CHF. By plotting CPO 
as a marker of cardiac contractility against systemic 
vascular resistance (SVR), the authors demonstrated that 
95% of patients could be categorized accurately into one 
of these syndromes [12]. Understanding the patho  physio-
logical mechanisms is key to management; for example, 
patients with cardiogenic shock and those with pulmo-
nary edema demonstrate a similar presentation with 
pulmonary congestion, clammy extremities, low cardiac 
output, and high wedge pressure. However, the patho-
physiologies are very diﬀ   erent and the treatments are 
almost opposite. Th   e former is characterized by low CPO 
and low SVR that requires inotropic support and 
occasionally peripheral vasoconstrictors, and the latter is 
characterized by extreme neurohormonal activation with 
higher values of CPO and very high SVR, necessitating 
aggressive peripheral vasodilation. According to this 
model, exacerbated systolic CHF, HTN crisis, and ACPE 
may be viewed as a continuum of progressive neuro-
hormonal activation leading to an increase in SVR with 
progressive recruitment of cardiac power reserve [8]. Th  e 
objective of treatment is then to optimize the SVR and 
thus the cardiac performance can be moved toward more 
optimal loading conditions to eﬀ  ect greater power output 
[13]. Th   e need for invasive hemodynamic monitoring is a 
limitation, but the advent of non-invasive tools could 
improve diagnosis, risk stratiﬁ  cation, and management of 
patients with AHFS.
Th  e etiology of heart failure and the cardiac rhythm 
inﬂ  uence the acute cardiac response to CPAP. In patients 
with dilated cardiomyopathy, CPAPs lead to a reduction 
in cardiac volumes, whereas in ischemic cardiomyopathy, 
there were small increases [14]. Similarly, atrial ﬁ  brilla-
tion resulted in a fall in cardiac index but there was a 
small rise in sinus rhythm [15].
CPAP, with its unique combination of respiratory and 
hemodynamic eﬀ  ects, will remain a cornerstone of the 
symptomatic treatment of ACPE. Future management 
should look beyond clinical risk scores to an 
understanding of etiology and pathophysiology in each 
patient to provide optimal treatment for this deadly 
condition.
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